Related Experiment Videos
Subependymal giant cell astrocytomas in children
G Sinson1, L N Sutton, A T Yachnis
1Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine 19104.
Pediatric Neurosurgery
|January 1, 1994
Summary
Subependymal giant cell astrocytomas (SEGAs) in children are rare pediatric brain tumors. Surgical resection offers a stable long-term outcome for most patients, with modern techniques improving safety.
Area of Science:
- Pediatric Neuro-oncology
- Neurosurgery
- Pediatric Oncology
Background:
- Subependymal giant cell astrocytomas (SEGAs) are rare pediatric brain tumors, accounting for 1.4% of cases.
- These tumors typically occur in children and adolescents, often associated with tuberous sclerosis.
Purpose of the Study:
- To review the clinical characteristics and outcomes of pediatric patients with SEGAs.
- To evaluate the effectiveness of surgical resection and modern surgical techniques in managing these tumors.
Main Methods:
- Retrospective review of 10 pediatric patients diagnosed with SEGAs between 1977 and 1991.
- Analysis of surgical approaches (frontal transventricular and transcallosal) and patient outcomes, including survival and tumor progression.
Main Results:
- Six out of ten patients achieved stable long-term follow-up (mean 6.7 years) after maximal surgical debulking or complete resection.
- Radiation therapy was ineffective in preventing tumor growth in one patient.
- Two perioperative deaths occurred, and two patients died from unrelated causes. Modern surgical techniques improved treatment safety.
Conclusions:
- Surgical resection is the primary treatment for pediatric SEGAs, with maximal debulking or complete resection leading to favorable outcomes.
- Advances in surgical techniques have enhanced the safety and efficacy of treating pediatric SEGAs.
- Long-term survival is achievable for most pediatric patients with SEGAs, even without adjuvant therapies.